Business Description
Eucrates Biomedical Acquisition Corp
NAICS : 551112
SIC : 6719
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.32 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.03 | |||||
Quick Ratio | 2.03 | |||||
Cash Ratio | 0.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | 2.94 | |||||
ROA % | 2.79 | |||||
ROIC % | -0.81 | |||||
3-Year ROIIC % | -0.05 | |||||
ROC (Joel Greenblatt) % | -487.26 | |||||
ROCE % | -0.81 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 49.46 | |||||
PE Ratio without NRI | 49.46 | |||||
PB Ratio | 4.95 | |||||
EV-to-EBIT | -60.56 | |||||
EV-to-EBITDA | -60.56 | |||||
EV-to-FCF | -67.1 | |||||
Earnings Yield (Greenblatt) % | -1.65 | |||||
FCF Yield % | -1.49 |